Model outcomes from the scenario analyses
| PHiD-CV vs PCV-13 | ||
|---|---|---|
| Scenario | Cost difference* (£) | QALY difference |
| Base case | −3 681 976 | 734 |
| No net herd protection | −3 681 967 | 734 |
| Serotype 3 efficacy against IPD=26% in PCV-13 | −3 669 466 | 731 |
| NTHi ID/pneumonia† included | −3 816 273 | 739 |
| Including productivity loss | −5 132 994 | 734 |
| Difference in list price‡ | −45 770 435 | 734 |
*Cost difference estimated on the basis of the number of consultations instead of episodes, using the RCGP 2011 weekly report data (from RCGP in England and Wales) and identical QALY gain assumed in deriving the associated ICER.
†Assumed incidence rate NTHi IPD 5% (expert opinion) and efficacy as in AOM; estimated incidence NTHi pneumonia cases 3% and percentage reduction in hospitalisation in accordance with efficacy in AOM.
‡In the UK, PCV-13 list price=£49.10 and PHiD-CV list price=£27.60.
AOM, acute otitis media; ICER, incremental cost-effectiveness ratio; ID, invasive disease; IPD, invasive pneumococcal disease; NTHi, non-typeable Haemophilus influenzae; PCV-13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine; QALY, quality-adjusted life-year; RCGP, Royal College of General Practitioners.